FDA: Serious Warnings Omitted From Ad Promoting Alcohol/Opioid Dependence Treatment
While claims about the benefits of Vivitrol were clearly presented in the ad, serious risks, such as vulnerability to opioid overdose, were not communicated.
While claims about the benefits of Vivitrol were clearly presented in the ad, serious risks, such as vulnerability to opioid overdose, were not communicated.
The FDA has approved the first generic versions of Gilenya (fingolimod; Novartis) for the treatment of relapsing forms of multiple sclerosis in adults.
A recent report published in the journal Neuropsychobiology describes the case of a 34-year-old woman with major depressive disorder whose symptoms improved following the initiation of an elimination diet.
A recent review published in the journal Pharmacotherapy summarizes recommendations for the treatment of Helicobacter pylori infection in special patient populations.
The US Preventive Services Task Force has issued final recommendations on the use of medications for primary prevention of breast cancer.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.